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Osteoclasts are multinucleated, terminally dif-
ferentiated cells from hematopoietic mono-
cyte/macrophage precursors responsible for 
bone resorption (degradation of mineralized 
matrix), a critical event regulating bone mass. 
Osteoclast diff  erentiation is regulated by multi-
ple factors, including macrophage colony-stim-
ulating factor (M-CSF) and receptor activator 
of NF-κB ligand (RANKL; also known as 
ODF and TRANCE) (1–4). Recently, trig-
gering receptors expressed by myeloid cells 
(TREM)2, a receptor of the immunoglobulin 
superfamily, DC-STAMP, a putative seven-
transmembrane receptor, and possible other 
RANK-independent receptors have been im-
plicated in osteoclast diff  erentiation  (5–11). 
Osteoclast activation is initiated upon cell at-
tachment to bone matrix, an event leading to 
osteoclast actin cytoskeletal reorganization and 
formation of sealing zones and a polarized ruf-
fl  ed membrane (12). When osteoclasts are cul-
tured on glass surfaces, unique cell adhesion 
structures, called podosomes and/or actin rings, 
are formed. They are related to, but distinct 
from, the typical focal adhesions formed in cul-
tured fi  broblasts or epithelial cells. Podosomes 
consist of a core of F-actin bundles surrounded 
by a rosette-like structure containing integrins 
(e.g., αvβ3) and actin-binding proteins, such as 
α-actinin and gelsolin (13–15). In addition, sig-
naling molecules are enriched at podosomes/
actin rings, including tyrosine kinases (c-Src 
and PYK2 [13, 16–18]), adaptor-like proteins 
(p130Cas [Crk-associated substrate; 19] and Cbl 
[a negative regulator of multiple tyrosine kinases; 
20, 21]), phosphatidylinositol-3 kinase (22), and 
rho family G proteins (23). Thus, stimulation 
of the αvβ3 integrin by cell attachment to 
bone matrix (e.g., vitronectin) elicits a series of 
biochemical responses, including activation of 
cytoplasmic tyrosine kinases, such as Src and 
PYK2, and subsequent tyrosine phosphorylation 
of several proteins including Cbl and p130Cas. 
These signaling molecules are essential for osteo-
clast actin cytoskeletal organization and function.
RAGE, a member of the immunoglobin 
superfamily of cell surface receptors, has been 
implicated in the pathogenesis of multiple 
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  disorders, including diabetic complications (24, 25), neuro-
degeneration (26), and infl  ammatory conditions (27). The 
link between RAGE and these pathological situations is the 
multiligand character of the receptor and its ability to sustain 
cellular activation (28). Ligands of RAGE include diabetes-
associated advanced glycation end products (24, 25), Al-
zheimer’s disease-associated amyloid β-peptide (26) and 
proinfl  ammatory-associated  Mac-1/β2 integrin (29), the 
S100 family, and high mobility group box (HMGB)1 (30). 
HMGB1, also called amphoterin or HMG1, is a nuclear pro-
tein released from activated macrophages or injured cells 
(31). Once in the extracellular space, HMGB1 displays pro-
infl   ammatory cytokine-like properties (31). Although the 
possible contribution of RAGE to pathologic states has been 
studied, the role of this receptor in homeostatic/physiologic 
settings has yet to be elucidated. Several lines of evidence 
suggest a role for RAGE in immune/infl  ammatory responses, 
beyond its capacity to bind proinfl  ammatory cytokines (32). 
For example, RAGE is involved in the recruitment of in-
fl  ammatory cells to activated endothelium (33–35). Engage-
ment of endothelial RAGE increases expression of vascular 
cell adhesion molecule-1, intercellular adhesion molecule-1, 
and endothelial cell selectin, and enhances adhesion of in-
fl   ammatory cells, such as neutrophils and monocytes, to 
stimulated endothelia (33–35). In addition, RAGE expres-
sion by activated endothelia promotes leukocyte recruit-
ment, via its interaction with myeloid cells expressing the β2 
integrin macrophage receptor 1 (29). Furthermore, studies 
using RAGE-defi  cient mice have shown the receptor to be 
important in innate immunity (32, 36). In sepsis induced by 
cecal ligation and puncture, a model largely dependent on 
the innate immune response, RAGE-defi  cient mice exhibit 
increased survival, which correlated with reduced local in-
fl  ammation and decreased NF-κB activation in target organs 
of septic shock (36). Such a protective phenotype in RAGE-
null animals in response to sepsis was reversed by restoring 
RAGE expression in hematopoietic and endothelial cells, 
suggesting an intrinsic role of RAGE in these cells. Among 
hematopoietic cells, macrophages have a key role in innate 
immunity and infl  ammation (36). However, the contribu-
tion of RAGE to macrophage diff  erentiation and activation 
remains to be fully elucidated.
Figure 1.  Morphologic and functional defects of in vitro–differ-
entiated RAGE mutant OCs. RAGE expression in BMMs and differen-
tiating osteoclasts (OCs) derived from WT and RAGE−/− mice was 
examined by Western blot analysis (A and C) and RT-PCR (B and D). In A 
and B, purifi  ed BMMs from WT mice were incubated with M-CSF (10%) 
for 2–3 d and then cultured in the presence of RANKL (100 ng/ml) and 
M-CSF (1%) for 0–5 d, as indicated. In C and D, pre-OCs and osteoclasts 
were generated from purifi  ed BMMs cultured in the presence of RANKL 
(100 ng/ml) and M-CSF (1%) for 2 and 4 d, respectively (see Materials 
and methods). In E, osteoclasts were generated from whole bone mar-
row (WBM) in the presence of 1,25(OH) vitamin D3 (see Materials and 
methods), and in F, osteoclasts were generated from purifi  ed BMMs 
cultured in the presence of RANKL (100 ng/ml) and M-CSF (1%) for 7 d. 
Morphologic characteristics of WT and RAGE−/− osteoclasts were deter-
mined by TRAP staining (E and F). Representative bone resorption 
caused by WT and RAGE−/− osteoclasts was visualized by Von Kossa 
staining (G). The bone resorption assay was performed by culturing 
osteoclasts on coverslips coated with calcium phosphate matrix for 8 d, 
and then staining coverslips with Von Kossa to display resorption pits 
(white) (see Materials and methods). Quantitative analysis of the aver-
age resorption area and pit number based on data from G is shown in 
H. **, P < 0.01, signifi  cant difference from the WT (Student’s t test). 
Green arrows in E and F indicate DCs, and red arrows in G indicate re-
sorptive pits.  Bars, 50 μm.JEM VOL. 203, April 17, 2006  1069
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Here, we identify RAGE as an essential factor in the reg-
ulation of osteoclast maturation and function. Using gene-
targeted mice, we show that RAGE defi  ciency leads to 
morphologically and functionally disrupted osteoclasts and an 
osteopetrosis-like phenotype. In addition, we provide evi-
dence for impaired osteoclast terminal diff  erentiation and 
  reduced integrin-mediated cell adhesion signaling in bone 
marrow macrophages (BMMs) and prefusion osteoclasts (pre-
OCs) derived from RAGE mutant mice. These results sug-
gest a novel role of RAGE in osteoclast maturation/function 
and bone remodeling. In addition, our fi  ndings provide in-
sight into a mechanism for regulation of cell adhesion by 
RAGE and imply a conserved function of RAGE in cells of 
monocyte/macrophage lineage.
RESULTS
Morphological and functional defects 
of in vitro–differentiated RAGE−/− osteoclasts
RAGE is highly expressed in hematopoietic cells, including 
BMMs (Fig. 1, A and B). Its expression detected by Western 
blot and RT-PCR analyses appeared to be up-regulated dur-
ing osteoclast diff  erentiation (Fig. 1, A and B). However, the 
role of RAGE in osteoclast diff  erentiation and function is un-
clear. To address this question, in vitro osteoclastogenesis was 
examined using cultures of whole bone marrow cells derived 
from WT and RAGE-defi  cient (RAGE−/−) mice under os-
teoclastogenic conditions, in which stromal cells (precursors of 
osteoblasts) provide M-CSF and RANKL, two essential factors 
for osteoclast development (1–4). BMMs derived from 
RAGE−/− mice showed undetectable RAGE expression (Fig. 
1, C and D), confi  rming the presence of a null allele in the 
mutant mouse (37). It is of interest to note that BMMs diff  er-
entiated from RAGE−/− bone marrow cultures appeared 
smaller in size compared with cells from WT cultures, although 
they were positive for tartrate-resistant acid phosphatase 
(TRAP), a marker of the osteoclast diff  erentiation (Fig. 1 E). 
These results suggest a morphologic defect in in vitro–diff  er-
entiated RAGE−/− osteoclasts, which could reside in stromal 
cells that failed to produce suffi   cient amounts of M-CSF and/
or RANKL or in osteoclastic precursors (e.g., macrophages).
Thus, we examined whether RAGE defi  ciency impaired 
the capacity of osteoclastic precursors to respond to M-CSF 
Figure 2.  Increased bone mass in 4-wk-old RAGE−/− mice. (A) Pixus 
densitometric analysis of the BMD of whole bone mass from 4-wk-old WT 
and RAGE−/− mice. Increased BMD was observed in RAGE−/− mice. (B) Radio-
graphic analysis of 4-wk-old WT and RAGE−/− mice. Femurs and tibiae from 
RAGE−/− mice show increased density of both cortical (empty arrows) and 
trabecular (fi  lled arrows) bones. (C) μ-CT images of femurs isolated from 
control C57BL/6 (WT) and RAGE−/− mice. Note that an increased bone length 
and increased trabecular and cortical bone mass were observed. The cross 
section images corresponding to the indicated position (yellow and green 
lines) were shown in D. Quantitative analysis of the ratio of BV/TV at the 
different positions of femurs from WT and RAGE−/− was shown in E. Three-
dimensional images of tibia isolated from WT and RAGE−/− mice were shown 
in F. Increased cortical (yellow) and trabecular (purple) bone mass was indi-
cated. (A and F) *, P < 0.05, signifi  cant difference from WT (Student’s t test). 1070  RAGE REGULATION OF OC ACTIVATION | Zhou et al.
and/or RANKL in vitro. To this end, purifi  ed BMMs from 
WT and RAGE−/− mice were exposed to M-CSF and 
RANKL for 7 d to induce osteoclastic diff  erentiation. Cul-
tures of WT BMMs formed confl  uent sheets of large TRAP-
positive cells, and >80% of these cells displayed typical 
spread, multinucleated characteristics of in vitro–diff  erenti-
ated osteoclasts (Fig. 1 F). However, RAGE−/− cultures, al-
though rich in BMMs, contained only smaller, poorly spread, 
but TRAP-positive multinucleated cells (Fig. 1 F). Only 
 20% of the multinucleated cell population displayed spread 
morphology, consistent with the defect of in vitro osteoclas-
togenesis observed in cultures of whole bone marrow cells. 
As this experiment was performed using purifi  ed BMMs, the 
osteoclastogenic defect in RAGE−/− whole marrow cultures 
may reside in osteoclast precursors, but not in cytokine-pro-
ducing stromal cells. In addition to the morphologic defects 
of in vitro–diff  erentiated osteoclasts, RAGE−/− TRAP-posi-
tive cells exhibited functional defects in bone resorption with 
signifi  cantly reduced numbers and average sizes of pits (Fig. 
1, G and H). Collectively, these results indicate that RAGE 
defi  ciency leads to generation of morphologically and func-
tionally impaired osteoclasts, suggesting a role for RAGE in 
regulating osteoclastic diff  erentiation and function in vitro.
Defects of osteoclast function in RAGE−/− mice
We next determined whether RAGE regulates osteoclast 
diff  erentiation and function in vivo by examining bone mass 
in RAGE−/− mice, as osteoclasts play a critical role in main-
tenance of healthy bone. Pixus densitometric analysis showed 
a  signifi   cant increase in bone mineral density (BMD) of 
whole bones in 4-wk-old RAGE−/− mice compared with 
that of age- and strain-matched WT mice (Fig. 2 A), suggest-
ing an increase of bone mass in RAGE mutant mice. The 
latter possibility was further supported by radiographic (Fig. 
2 B) and microcomputer tomographic (μCT) analyses. 4-
wk-old RAGE−/− mice displayed an increase in the density 
of trabecular and cortical bone area in femurs and tibia (Fig. 
2, C–F). These results implicate a defect of osteoclast func-
tion in RAGE−/− mice. To test this concept, serum deoxy-
pyridinoline (Pyd), an indicator of bone resorption (collagen 
matrix degradation) in vivo, was measured in WT and 
RAGE−/− mice. Indeed, Pyd in sera of RAGE−/− mice was 
signifi  cantly reduced (Fig. 3 A) compared with that in WT 
mice, confi  rming a role for RAGE in regulating osteoclast 
function in vivo.
These results led us to evaluate the possible involvement 
of RAGE in osteoclast diff  erentiation in vivo by histological 
examination of WT and RAGE−/− femur and tibia. The 
number of osteoclasts per unit bone volume (unpublished 
data) and the total number of osteoclasts per unit resorptive 
surface was reduced in RAGE−/− tibia and femurs (Fig. 3 D). 
Consistent with impaired function of osteoclasts in RAGE−/− 
mice, bone volume (over the total volume, or the total bone 
volume) was increased in femur from these animals (Fig. 3, 
B–C and E). Based on these observations, we propose that 
RAGE contributes to osteoclast function in vivo.
Defective 𝗂v𝗃3-dependent signaling in RAGE−/− BMMs 
and pre-OCs
Impaired osteoclastogenesis in vitro led us to examine 
whether M-CSF and/or RANKL signaling in RAGE−/− 
BMMs was altered. M-CSF and its receptor, c-Fms, drive 
Figure 3.  Decreased bone resorptive activity and increased bone 
volume in RAGE−/− mice. (A) Measurement of serum Pyd levels in WT 
and RAGE−/− mice by ELISA. (B and C) Quantitative analysis of trabecular 
bone of WT and RAGE−/− mice expressed as the percentage of trabecular 
bone volume versus total marrow space (BV/TV) (B) or as total bone vol-
ume (C). n = 3. (A–D) * P < 0.05, signifi  cant difference from WT (Stu-
dent’s t test). (D) Quantitative analysis of the number of osteoclasts in WT 
and RAGE−/− tibia and femurs expressed as total osteoclast number per 
bone resorptive surface (mm) (fi  elds counted per each slide = 5, n = 3). 
(E) Histomorphologic analysis of sections of femurs from 4-wk-old WT 
and RAGE−/− mice. Histologic sections of femurs were stained for TRAP 
activity (purple) to identify OCs and counterstained with methyl green to 
visualize cortical thickness and trabecular mass.JEM VOL. 203, April 17, 2006  1071
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early lineage development from BMMs and are essential for 
osteoclastic survival (2). WT and RAGE−/− BMMs prolifer-
ated equally in response to M-CSF (unpublished data), sug-
gesting the absence of a defect in the early stage of the 
response of RAGE−/− BMMs to M-CSF. Indeed, M-CSF–
induced phosphorylation of extracellular signal–regulated ki-
nase (Erk1)/2 and AKT/PKB (protein kinase B) was normal 
in RAGE−/− BMMs (Fig. 4 A). We then examined RANKL 
signaling responses in RAGE−/− BMMs. RANKL and its 
  receptor, RANK, are essential for the development of BMMs 
to mature osteoclasts (3, 4). RANKL activation of NF-κB 
and Erk1/2 is required for effi   cient osteoclastogenesis (1). 
Notably, RANKL-driven phosphorylation of Erk1/2 and 
Akt (Fig. 4 B) and RANKL-induced activation of NF-κB, 
assessed by IκB-α phosphorylation (Fig. 4 B) and nuclear 
translocation of p65 (unpublished data), appeared to be nor-
mal in RAGE−/− BMMs. These results suggest that RAGE 
has no or little eff  ect on M-CSF– or RANKL-induced early 
signaling events in BMMs.
We next examined whether αvβ3-mediated signaling was 
impaired in RAGE−/− BMMs and pre-OCs, as integrin 
αvβ3-mediated cell adhesion plays an essential role in osteo-
clastic maturation and function (12). WT or RAGE−/− 
BMMs and pre-OCs were plated on dishes coated with vit-
ronectin (VN), a ligand for αvβ3. Tyrosine phosphorylation 
of PYK2 (PY402) and phosphorylation of Erk1/2 were ex-
amined, as they are “activated” by engagement of integrin 
αvβ3 in BMMs and pre-OCs (Figs. 4, C and D). Remark-
ably, these signaling events were attenuated or blocked in 
RAGE−/− BMMs or pre-OCs (Figs. 4, C and D), demon-
strating an impairment of αvβ3-mediated signaling in 
RAGE−/− cells. Moreover, this event appeared to be spe-
cifi   c, since M-CSF–induced Src and Erk phosphorylation 
were unaff  ected in RAGE−/− BMMs (Fig. 4 and unpub-
lished data). Collectively, these results suggest a critical role of 
RAGE in regulating integrin- (i.e., αvβ3) mediated signaling 
in osteoclast precursors.
Defects of actin cytoskeletal organization and terminal 
differentiation in in vitro–cultured RAGE−/− osteoclasts
Integrin engagement leads to actin cytoskeletal reorga-
nization and formation of actin rings and podosomes in 
Figure 4.  Defective 𝗂v𝗃3-dependent signaling in RAGE−/− 
BMMs and pre-OCs. M-CSF (A) and RANKL (B) signaling in BMMs 
derived from WT and RAGE−/− mice were studied by Western blot 
  analysis of the phosphorylated p42/p44 form of Erk (p-Erk), AKT (p-
AKT), or IκB (p-IκB) at the indicated times. Levels of total Erk, AKT, or 
β-actin were used as controls for protein loading. In C and D, VN-
  stimulated signaling was determined by Western blot analysis for the 
presence of phosphorylated tyrosine at residue 402 in PYK2 (PY402) 
and phosphorylated Erk (p-Erk). Total PYK2, Erk, or β-actin levels were 
used as loading controls. BMMs (C) and pre-OCs (D) derived from WT 
and RAGE−/− mice were lifted and replated onto VN-coated dishes for 
the indicated times or left in suspension (0 min).1072  RAGE REGULATION OF OC ACTIVATION | Zhou et al.
osteoclasts, a process essential for osteoclast function (12). 
The defects in integrin signal transduction in RAGE−/− pre-
OCs led us to examine F-actin structures in RAGE−/− 
  osteoclasts cultured on glass by phalloidin staining. RAGE−/−, 
TRAP-positive multinucleated cells showed membrane ruf-
fl  es, contrasting with a belt of podosomes/actin rings along 
the peripheral membranes of WT osteoclasts (Fig. 5 A). 
In addition, loss of RAGE in BMMs resulted in a signifi  -
cantly reduced number of actin ring–containing cells (Figs. 
5, A and D). Moreover, the average number of podosomes 
per unit area and the average number of nuclei per multi-
nucleated cell were reduced in RAGE−/− osteoclasts (Figs. 
5 A, B, E, and F). The latter situation is reminiscent of that 
seen in partially diff  erentiated osteoclasts.
Figure 5.  Defects of actin-based cytoskeletal organization in 
RAGE−/− osteoclasts. Osteoclasts differentiated from BMMs of WT 
and RAGE−/− mice were cultured on glass and visualized with phalloi-
din (for the actin cytoskeleton) and DAPI (for nuclei). A shows lower 
magnifi  cation images, and B and C show higher magnifi  cation images. 
The arrows in A and B indicate OCs.  The quantitative areas are indi-
cated by rectangular boxes in B. The green horizontal lines in C indicate 
the positions of z axis for the measurement of the heights of OCs. 
(D) Quantifi  cation of the percentage of osteoclasts with intact actin ring 
structures. (E) Quantifi  cation of the number of nuclei per osteoclast. 
(F) Quantifi  cation of the number of podosomes per indicated area in B. 
(G) Osteoclast height from WT and RAGE−/− cells was determined by con-
focal microscopy as the mean distance from the matrix surface to the 
apex of the basolateral membrane of single osteoclasts plated on glass 
and stained with phalloidin. **, P < 0.01, signifi  cant difference from 
WT (Student’s t test).JEM VOL. 203, April 17, 2006  1073
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To evaluate whether the inability of RAGE−/− osteo-
clasts to generate actin rings leads to nonpolarized and, hence, 
dysfunctional osteoclasts, we measured the distance between 
the basolateral membrane facing the marrow space and the 
ruffl   ed border (osteoclast height), which is used as an index 
of osteoclast polarization (38). RAGE−/− osteoclasts showed 
signifi  cantly reduced height compared with WT osteoclasts 
(Fig. 5 G), indicating defective osteoclast polarization. These 
results suggest that disrupted actin cytoskeletal organization 
in RAGE−/− osteoclasts may be responsible for the morpho-
logic and functional defects observed in vitro and in vivo.
To examine whether RAGE−/− osteoclasts have defects 
in terminal diff  erentiation/maturation, we examined expres-
sion of osteoclastogenic markers (matrix metaloproteinase 9 
[MMP9], cathepsin K, TRAP, and calcitonin receptor) in 
WT and RAGE−/− BMMs cultured with RANKL and 
M-CSF using RT-PCR analysis. Although transcripts encoding 
these markers were induced by day 2 in WT cultures, this 
event was delayed until day 4 in RAGE−/− cultures (Fig. 6 A). 
In addition, induction of the calcitonin receptor, a marker of 
mature osteoclasts, was completely abolished in RAGE−/− 
cultures for 5 d (Fig. 6 A), consistent with impaired osteoclast 
(OC) maturation. Collectively, these results implicate RAGE 
in osteoclastic actin cytoskeletal organization and suggest a 
role for RAGE in osteoclast maturation.
Down-regulated expression of 𝗂v𝗃3, 𝗂-actinin, 
and paxillin in RAGE−/− pre-OCs
Defects in vitronectin integrin–induced signal transduction 
in RAGE−/− cells led us to address whether expression of 
αvβ3, integrins for VN, is altered in RAGE mutant cells. 
RT-PCR analysis demonstrated enhanced expression of αvβ3 
in WT cultures during osteoclast diff  erentiation (Fig. 6 A). 
However, this induction was delayed and reduced in 
RAGE−/− cultures (Fig. 6 A). In addition, podosome/actin 
ring-associated proteins, α-actinin, paxillin, and PYK2 were 
up-regulated in WT pre-OCs (day 3 in culture) (Fig. 6 B). 
Increased expression of paxillin and α-actinin, but not PYK2, 
was also inhibited in RAGE−/− pre-OCs (Fig. 6 B). Collec-
tively, these results suggest a role of RAGE in the expression 
of αvβ3, α-actinin, and paxillin during osteoclast diff  erentia-
tion. Such RAGE-mediated expression of genes/proteins 
may be critical for regulation of actin cytoskeletal organiza-
tion in pre-OCs.
Inhibition of c-Fos and NFATc1 expression induced 
by RANKL and M-CSF in RAGE−/− pre-OCs
To further understand how RAGE regulates osteoclast matu-
ration and function, we examined expression of transcrip-
tional factors essential for osteoclastogenesis, including c-Fos 
and NFATc1 (39, 40). WT BMM cultures in the presence of 
Figure 6.  Impaired osteoclast maturation and induction of 
NFATc1, integrins (𝗂v𝗃3), 𝗂-actinin, and paxillin in RAGE−/− pre-
OCs. (A) RT-PCR analysis to assess expression of transcripts for MMP9, 
cathepsin K (Cath K), TRAP, calcitonin receptor (Calc R), integrins β3 and 
αv, and NFATc1 in in vitro WT and RAGE−/− BMMs cultures in the pres-
ence of RANKL (100 ng/ml) and M-CSF (1%) for the indicated days. 
GAPDH was used as an internal control. (B) Western blot analysis of the 
expression of α-actinin, paxillin, PYK2, and actin in WT and RAGE−/− 
BMMs (day 0) and pre-OCs (day 3). (C) Western blot analysis of the 
expression of NFATc1, c-Fos, and actin in WT and RAGE−/− BMMs cul-
tures in the presence of RANKL (100 ng/ml) and M-CSF (1%) for the 
indicated days.1074  RAGE REGULATION OF OC ACTIVATION | Zhou et al.
M-CSF and RANKL showed an increase of c-Fos expression 
at day 1 and sustained induction of NFATc1 at both 
RNA and protein levels (Fig. 6, A and C). In contrast, such 
induction of c-Fos and NFATc1 was abolished in RAGE−/− 
cultures (Fig. 6, A and C). Note that immunoreactive 
NFATc1 migrated more rapidly in WT cells after exposure 
to RANKL and M-CSF (Fig. 6 C), probably caused by 
RANKL/M-CSF–induced activation of a calcium/calcineu-
rin that caused dephosphorylation of NFATc1. This event 
was also abolished in RAGE−/− cells, indicating a role of 
RAGE in NFATc1 activation and induction (Fig. 6 C).
Inhibition of convergent signal transduction induced 
by 𝗂v𝗃3 integrin engagement and M-CSF 
in RAGE−/− BMMs and pre-OCs
It has been reported that c-Fms and αvβ3 collaborate in osteo-
clastogenesis via shared activation of Erk signaling pathways 
critical for osteoclastic maturation (41, 42). Higher concen-
trations of M-CSF are capable of rescuing phenotypes associ-
ated with integrin β3-defi  cient cells (42). Down-regulation of 
αvβ3 expression in RAGE−/− cells led us to examine whether 
RAGE−/− cells behave similarly to β3
−/− cells, whose phe-
notypes can be rescued by high dose of M-CSF treatment. 
Thus, we examined whether higher doses of M-CSF (e.g., 
10%) could rescue signaling defects (e.g., PYK2 and Erk 
phosphorylation) in response to αvβ3 integrin engagement in 
RAGE−/− BMMs and pre-OCs. BMMs or day 3 pre-OCs 
generated from WT and RAGE−/− mice were lifted and re-
plated on VN-coated dishes in the absence of serum. After 
treatment with M-CSF at lower (1%) or higher (10%) doses 
for diff  erent times, adherent cells were lysed and phosphory-
lation of PYK2, Src, and Erk1/2 and c-Fos activation/induc-
tion were examined. Although phosphorylation of PYK2 and 
Erk1/2 and c-Fos activation were induced by M-CSF at a 
low dose in WT BMMs, activation of these proteins was re-
duced or inhibited in RAGE−/− BMMs (Fig. 7 A), suggesting 
a defect of the convergent signaling by integrin engagement 
and M-CSF in RAGE−/− BMMs. Such signaling defects in 
BMMs could be rescued by treatment with a high dose of 
M-CSF; thus, M-CSF at 10% (a high dose) did induce PYK2 
Figure 7.  Requirement of RAGE for the convergent signal trans-
duction induced by 𝗂v𝗃3 integrin engagement and M-CSF. BMMs 
(A, B, and D) and pre-OCs (C) from WT and RAGE−/− mice were lifted and 
replated on VN-coated dishes in the absence of serum. Adherent cells 
were treated with M-CSF at the indicated doses (A–C) or RANKL (D) 
for the indicated times and lysed. Equal amounts of total proteins were 
immunoblotted with the indicated antibodies, or pulled-down by GST-
PBD to isolate GTP-bound Rac proteins (see Materials and methods).JEM VOL. 203, April 17, 2006  1075
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and Erk phosphorylation and c-Fos activation/induction (Fig. 
7 B). In contrast, M-CSF, even at a high dose, failed to in-
duce PYK2, Src, or Erk phosphorylation in RAGE−/− pre-
OCs (Fig. 7 C). The latter observation suggests only a partial 
rescue of the RAGE−/− signaling defect by exposure to a high 
level of M-CSF in cells which have progressed down the 
  osteoclast diff  erentiation pathway. Consistent with these re-
sults, impaired osteoclast generation in RAGE−/− cultures 
could not be rescued by increasing M-CSF by amounts up to 
10-fold (Fig. 8 A) or RANKL up to 4-fold (Fig. 8 B) com-
pared with optimal doses for WT cultures. This situation 
contrasts with observations in integrin β3 mutant cells, where 
higher concentrations of M-CSF do rescue the phenotype 
(42), but is reminiscent of that seen in TREM/DAP12 
mutant cells (43).
In addition to PYK2, Src, and Erk, Rho family GTPases 
(e.g., Rac) known to be essential for actin cytoskeletal re-
organization and cell spreading in OCs are also activated by 
M-CSF and integrin engagement (38). In view of impaired 
actin cytoskeletal organization and cell spreading observed in 
RAGE−/− pre-OCs, we assessed whether Rac activation by 
integrin engagement and M-CSF was inhibited. Indeed, de-
letion of the RAGE gene reduced Rac1 activation in response 
to M-CSF and integrin engagement compared with WT cells 
(Fig. 7 C). Collectively, these results suggest a requirement 
for RAGE in regulating the convergence of αvβ3 integrin- 
and M-CSF–mediated signals, which include activation of 
Rac, in addition to PYK2, Src, Erk, and c-Fos, in pre-OCs.
We also assessed whether RAGE is involved in the cross 
talk of the signaling transduction induced by RANKL and 
integrin engagement. To this end, BMMs generated from 
WT and RAGE−/− mice were lifted and replated on VN-
coated dishes in the absence of serum. After treatment with 
RANKL for diff  erent times, adherent cells were lysed and 
phosphorylation of PYK2 and Erk1/2 and c-Fos activation/
induction were examined. As shown in the Fig. 7 D, al-
though integrin engagement appeared to enhance RANKL-
induced Erk activation, the eff  ect of RAGE in this event was 
minimal, suggesting that RAGE may not be involved in such 
cross talk between integrin and RANKL.
DISCUSSION
RAGE, a multiligand receptor, contributes to the pathogen-
esis of multiple disorders, including diabetic complications, 
neuronal degeneration, and infl  ammatory disorders (32). In 
this study, we present evidence for a role of RAGE in regu-
lating osteoclast maturation, function, and bone remodeling, 
which lead us to propose the model depicted in Fig. 9. 
Figure 8.  Morphologic defects of RAGE−/− BMMs induced to dif-
ferentiate in the presence of varying doses of M-CSF and RANKL. 
BMMs from WT and RAGE−/− mice were cultured in the presence of the 
indicated concentrations of M-CSF and 200 ng/ml of RANKL (A) or in 
the presence of the indicated concentrations of RANKL and 5% of 
M-CSF (B). After 6 d of the treatment, TRAP staining was performed. 
The solid arrows in A and B indicate OCs in WT, and the open arrows 
 indicate  RAGE−/− OCs. Bar (applies to A and B), 50 μm.1076  RAGE REGULATION OF OC ACTIVATION | Zhou et al.
  According to this model, RAGE, in response to its ligands, 
regulates convergent signals induced by integrin engagement 
and M-CSF that lead to actin cytoskeletal remodeling and 
osteoclastic maturation/activation (Fig. 9). Because of the 
dynamic nature of changes in the skeleton at young ages, dif-
ferent results might be obtained at later stages of bone devel-
opment. However, based on the data presented here, we 
speculate that deletion of the RAGE gene might aff  ord rela-
tive protection for the skeletal system in situations such as 
  diabetes- or menopause-associated osteoclast activation.
Osteoclasts are tissue-specifi   c macrophage polykaryon 
generated by the diff  erentiation of monocyte/macrophage 
precursors at or near the bone surface. Close contact between 
stromal and bone marrow cells is essential for osteoclastogen-
esis in vivo, as stromal-derived factors, M-CSF and RANKL, 
activate receptors on BMMs, thereby stimulating osteoclast 
diff  erentiation (1, 44). In addition to M-CSF and RANKL, 
Ig family receptors (e.g., TREM2) and integrin αvβ3 engage-
ment play a crucial role in osteoclast terminal diff  erentiation/
maturation and function (8, 12, 45). Mice lacking TREM2 
or αvβ3 show increased bone mass and develop osteosclerosis 
(7, 46). In this context, deletion of the gene for DAP12, a 
downstream mediator of TREM2 (7), or Src, a cytoplasmic 
tyrosine kinase whose activation depends on integrin engage-
ment, results in mice with similar osteosclerotic phenotypes 
(16, 18, 20). In these mutant mice, osteoclast terminal diff  er-
entiation/maturation is blunted in vitro (6, 7, 16, 18, 20). 
Moreover, actin cytoskeletal organization, e.g., actin ring and 
podosome formation, is disrupted in osteoclasts derived from 
these mutant animals (6, 7, 16, 18, 20, 43). Furthermore, the 
induction of NFATc1 by RANKL and M-CSF is abolished 
in TREM2/DAP12–defi  cient cells (5). In the current study, 
we demonstrate that RAGE−/− mice exhibit similar pheno-
types to those observed in integrin β3, Src, TREM2, and 
DAP12-defi  cient mice (46, 47), suggesting functional simi-
larity of Ig family receptors, RAGE and TREM2, and impli-
cating potential cross talk between RAGE and integrin 
αvβ3-mediated signaling pathways.
There is convergence of signaling downstream from c-Fms 
and αvβ3 integrins which contributes to osteoclast maturation 
and function (42). Thus, high doses of M-CSF can rescue the 
phenotypes observed in β3
−/− mice (42). However, mor-
phologic abnormalities in RAGE−/− pre-OCs failed to be 
rescued by higher doses of M-CSF, suggesting a diff  erence 
between RAGE−/− and β3
−/− mice. Moreover, sustained 
Erk activation is proposed to be a convergent signal conse-
quent to engagement of c-Fms and αvβ3 integrins in osteo-
clast maturation (42). The latter event is inhibited in 
RAGE−/− pre-OCs, consistent with the observed inability of 
M-CSF to rescue RAGE−/− morphologic phenotypes and 
supporting a role for sustained Erk activation in osteoclast 
diff   erentiation/maturation. Furthermore, serum M-CSF is 
increased in β3
−/− (42), but not in RAGE−/− mice (unpub-
lished data), which is believed to play an important role in 
rescuing osteoclast diff  erentiation in β3
−/− mice (42). Col-
lectively, these observations implicate a role of RAGE in the 
convergent signaling mechanisms linking c-Fms and integrin 
αvβ3, and suggest that convergent downstream signals includ-
ing activation of PYK2, Src, Rac, and Erk are altered in 
RAGE−/− pre-OCs. In this context, we speculate that 
PYK2/Src/Rac may be important convergent signals regu-
lated by multiple receptors including integrins, c-Fms, and 
RAGE. This mechanism might be involved in sustained acti-
vation of MAPKs (Erk and JNK) and induction of transcrip-
tion factors (c-Fos and NFATc1) (Fig. 9). This concept is 
consistent with the observation that integrin engagement 
  appears to be a permissive factor for activation of PYK2, Src, 
and Rac by M-CSF, and that activation of PYK2, Src, or 
Rac is suffi   cient to stimulate Erk/JNK in diff  erent cells (48).
Mechanisms underlying RAGE-mediated regulation of 
integrin signaling remain to be delineated, though multiple 
pathways may be involved. We hypothesize that RAGE may 
regulate integrin signaling at the transcriptional level, at the 
cell surface (by possible direct association with integrins), and 
intracellularly. The observed decreased expression of integ-
rins (αvβ3) in RAGE−/− pre-OCs supports a role for RAGE 
Figure 9.  A working hypothesis for RAGE-mediated regulation of osteoclast maturation and function.JEM VOL. 203, April 17, 2006  1077
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in regulation of integrin expression at the transcriptional 
level, though the mechanism is unclear. We speculate that 
sustained Erk and c-Fos activation and induction of NFATc1 
may have critical roles in this event. These observations do 
not exclude the possibility that RAGE might regulate integ-
rin signaling via direct binding to integrins. In this context, 
endothelial RAGE has been shown to associate with β2 inte-
grins in leucocytes (29). Thus, it would be of interest to ex-
amine whether RAGE-bearing BMMs or osteoclasts can 
interact with the same cells (i.e., in cis) bearing β2 integrins, 
thereby resulting in an autocrine regulatory loop.
In addition, we speculate that RAGE may be critical for 
PYK2 and sustained Erk activation by integrin and c-Fms 
engagement, events required for expression of integrin β3, 
α-actinin, and paxillin during osteoclast maturation (Fig. 9). 
This notion is supported by previous reports that RAGE 
plays a crucial role in sustained Erk activation in multiple cell 
types (49, 50) and that sustained Erk activation is required for 
expression of β3 (41). What are possible underlying mecha-
nisms? Binding of ligands to RAGE on diff  erent cells such as 
endothelial cells, neurons, smooth muscle cells, or monocytes 
has been shown to activate a range of signaling pathways 
  including Erk1/2 (p44/p42), p38 and JNK MAP kinases, 
rho GTPases, phosphoinositol 3-kinase, and the JAK/STAT 
pathway, as well as NF-κB signaling (32, 51). In addition, 
RAGE engagement can trigger generation of reactive oxy-
gen species (ROS), at least in part via activation of NADPH 
oxidase (52–54). We speculate that RAGE-dependent ROS 
generation may underlie PYK2 and sustained Erk phosphor-
ylation during osteoclast diff  erentiation. In this context, it is 
relevant that ROS can be induced by M-CSF and RANKL 
in BMMs, and such ROS appear to be required for osteoclast 
actin ring formation and osteoclastic maturation and function 
(55–57). However, whether RAGE regulates integrin signal-
ing through similar mechanisms remains to be determined.
In summary, we provide evidence for a contribution of 
RAGE to osteoclast maturation and function which is consis-
tent with the receptor’s emerging role in dendritic cell matu-
ration/function (58, 59). These observations implicate RAGE 
more generally in the maturation of monocyte/macrophage 
lineage cells, an important cellular process for innate immu-
nity and infl  ammatory responses. In addition, our results sug-
gest that RAGE may function as a costimulatory receptor 
similar to other ITAM Ig family receptors (e.g., TREM2), 
thereby delivering essential signals for terminal osteoclastic 
diff  erentiation, in concert with RANKL, M-CSF, and integ-
rin-mediated signaling cascades (5, 7, 8, 39). Furthermore, 
our results suggest that RAGE may be an additional target 
for the design of therapeutic approaches to treat bone loss–
  related disorders.
MATERIALS AND METHODS
Reagents and animals. Antibody specifi  c to phospho-PYK2 (PY402) was 
purchased from Transduction Laboratories, Inc., and antibodies to phospho-
Src (mAb PY416), phospho-Akt (P-Akt), Akt, phospho-Erk1/2 (p-Erk1/2), 
and Erk1/2 were from Cell Signaling. Monoclonal anti-αvβ3 and NFATc1 
antibodies were purchased from Abcam, Inc. and BD PharMingen, respec-
tively. The c-Fos polyclonal antibody was from Santa Cruz Biotechnology, 
Inc. RAGE antibody (mAb) was purchased from Chemicon, and RAGE 
polyclonal antibody was generated by GST-RAGE COOH-terminal fusion 
protein. VN was obtained from Sigma-Aldrich. 1α,25-dihydroxyvitamin D3 
(1α, 25[OH]2D3) and collagenase were obtained from Wako Chemicals, and 
dispase was purchased from Roche. Murine M-CSF was obtained from 
R&D Systems. Recombinant GST-RANKL was generated and purifi  ed as 
described previously (60). RAGE−/− mice described previously (37) were 
crossed into C57BL/6 genetic background. Age-matched C57BL/6 WT 
mice were used as controls. RAGE mutation was confi  rmed by the expres-
sion of GFP, an indicator of the Cre expression in the mice (37), RT-PCR 
for its mRNA expression, and Western blot analysis. All experimental proce-
dures were approved by the Animal Subjects Committee at the Medical Col-
lege of Georgia, according to U.S. National Institutes of Health guidelines.
In vitro osteoclastogenesis using whole bone marrow cells. Bone 
marrow cultures were prepared using previously described methods with 
modifi  cations (13). In brief, the bone marrow was fl  ushed from femurs and 
tibiae with ice-cold α-MEM (GIBCO BRL). Cells were collected, pelleted, 
and resuspended in α-MEM supplemented with 10% FBS (Hyclone) and 
cultured in 6-well plates at a density of 2.5 × 106/cm2 for 7 d in the presence 
of 2.5 × 10−8 M 1,25(OH)2D3. At day 4 of culture, 90% of the medium 
with 1,25(OH)2D3 was replaced. At day 8, cultures were fi  xed and stained 
for TRAP using the Leukocyte Acid Phosphatase kit (Sigma-Aldrich).
In vitro osteoclastogenesis using purifi  ed BMMs. Mouse BMMs, pre-
OCs, and osteoclasts were generated as described (13). In brief, whole bone 
marrow cells were fl  ushed from long bones of 4–6-wk-old WT or RAGE−/− 
mice and plated on 100-mm tissue culture plates in α-MEM containing 10% 
FBS and 10 ng/ml recombinant M-CSF (R&D Systems). Cells were incu-
bated at 37°C with 5% CO2 overnight. Nonadherent cells were harvested 
and subjected to Ficoll-Hypaque gradient centrifugation for purifi  cation of 
BMMs. Isolated BMMs were then cultured in α-MEM containing 10% FBS 
plus 10 ng/ml recombinant M-CSF. To generate pre-OCs, BMMs were 
cultured in α-MEM containing 10% FBS in the presence of 10 ng/ml re-
combinant M-CSF and 100 ng/ml recombinant GST-RANKL for 2–3 d. 
To generate mature OCs, 5 × 104 BMMs were plated in one well of a 
24-well plate in α-MEM containing 10% FBS in the presence of 10 ng/ml 
recombinant M-CSF and 100 ng/ml recombinant GST-RANKL. Mature 
osteoclasts (multinucleated, large, spread cells) began to form at day 4 of 
  culture. The identity of osteoclasts was confi  rmed by TRAP staining.
In vitro resorption assay of cultured OCs. BMMs were replated in 16-
well BD BioCoat Osteologic slides (BD Biosciences), which are coated with 
inorganic hydroxyapatite matrix, in the presence of M-CSF (2%) and RANKL 
(100 ng/ml). After 8 d, cells were washed and stained with Von Kossa. Resorp-
tion pits were analyzed using National Institutes of Health Image software.
In vivo bone resorption assay. Mouse bone resorption activity was de-
termined by measuring serum Pyd concentration using METRA Serum 
PYD EIA kit (QUIDEL Corporation) according to the manufacturer’s in-
structions. In brief, fi  ltered serum samples (25 μl) were incubated with 75 μl 
Pyd antibody and reagent overnight at 4°C in the dark. After washing three 
times, samples were incubated with enzyme conjugate for 60 min at room 
temperature. Substrate solution (150 μl) was added to samples after washing 
and incubated at room temperature for 40 min. The reaction was stopped, 
and the OD was measured at 405 nm. OD was then converted to Pyd con-
centration using a standard curve. All the samples were measured in dupli-
cate, and values were subjected to statistical analysis.
Radiographic, densitometric, and 𝗍CT analysis of bone mass. A dual 
energy x-ray (DEXA) PIXImus densitometer was used to measure bone min-
eral density of whole bone mass from 4-wk-old mice. In addition, long bones 
(e.g., femurs and tibia) and spines were isolated from mice (4−6 wk old) 
and subjected to radiographic analysis using x-ray and μCT analysis. x-ray 1078  RAGE REGULATION OF OC ACTIVATION | Zhou et al.
  projection images were acquired from a custom in-house μCT system con-
sisting of a microfocal x-ray source, a 4-axis manipulator (Danaher Motion) 
and an amorphorous silicon fl  at panel image (Paxscan 4030; Varian Medical 
Systems). For a given examination, 570 projection images were acquired over 
360° rotation with an exposure time of 11.2 s for each image. The x-ray 
source was confi  gured with a 15-μm spot, 60 kV tube voltage, and 0.15 mA 
tube current. The x-rays were fi  ltered through 0.4 mm AL and 1.3 mm 
  Tefl  on. The samples were positioned to produce a geometric magnifi  cation 
of 8.5 resulting in a reconstruction voxel size of 15 μm. Three-dimensional 
reconstruction was performed by Lawrence Livermore National Laboratory 
software using the Feldkamp cone-beam algorithm. Three-dimensional sur-
facing was performed using IDL software (Research Systems, Inc.). Bone 
volume (BV) to tissue volume (TV) ratio measurements were generated by 
fi  rst segmenting the calcifi  ed bone tissue with an appropriate threshold level 
and then dividing the number of these segmented bone tissue voxels by the 
number of voxels enclosed by the same segmentation threshold level.
Bone histomorphometric analysis. Mouse tibia and femurs were fi  xed 
overnight in 10% buff  ered formalin, decalcifi  ed in 14% EDTA, embedded in 
paraffi   n, sectioned, and stained for TRAP with a methyl green counterstain. 
Bone histomorphometric perimeters were determined by measuring the 
  areas situated at least 0.5 mm from the growth plate, excluding the primary 
spongiosa and trabeculae connected to the cortical bone.
Immunofl  uorescence. WT and RAGE−/− osteoclasts cultured on glass 
were fi  xed and stained with Texas red–phalloidin as previously described 
(13). To measure osteoclast height, the distance between the basolateral 
membrane (top of the cell) and the ruffl   ed border (bottom of the cell, facing 
the matrix) was determined using confocal microscopy.
Western blot analysis. BMMs or pre-OCs were cultured and then starved 
overnight in serum-free media. Cells were lifted and replated on VN for the 
indicated times. For some experiments, cells were further stimulated with 5 
ng/ml M-CSF followed by lysis in RIPA buff  er described previously (61). 
Lysates were subjected to SDS-PAGE and immunoblotting analysis using 
the indicated antibodies.
RT-PCR analysis. Total RNA was prepared from BMMs, pre-OCs, 
and osteoclasts derived from WT and RAGE−/− mice using Trizol (Invi-
trogen). These cells were generated as described (see In vitro osteoclasto-
genesis using purifi  ed BMMs), at day 0 (BMMs), day 2 (pre-OCs), and day 
4 (osteoclasts) in culture in the presence of M-CSF and RANKL. cDNAs 
were synthesized from 2 μg of total RNA using SuperScript III First Strand 
Synthesis System (Invitrogen) in a volume of 20 μl. The reaction mixture 
was adjusted to 100 μl with distilled water. One microliter of cDNA was 
amplifi  ed with the specifi  c primers indicated by PCR. The PCR product 
was separated on a 1.5% agarose gel and visualized by ethidium bromide 
staining. The following primers were used: integrin αv, 5′-A  A  C  A  T  C  A  C-
C  T  G  G  G  G  C  A  T  T  C  A  -3′ and 5′-C  G  T  C  A  G  T  G  T  G  G  G  C  G  A  A  G  T  A  A  A  -3′; 
integrin β3, 5′-T  T  A  C  C  C  C  G  T  G  G  A  C  A  T  C  T  A  C  T  A  -3′ and 5′-A  G  T  C  T  T-
C  C  A  T  C  C  A  G  G  G  C  A  A  T  A  -3′; calcitonin receptor, 5′-C  A  T  T  C  C  T  G  T  A  C-
T  T  G  G  T  T  G  G  C  -3′ and 5′-A  G  C  A  A  T  C  G  A  C  A  A  G  G  A  G  T  G  A  C  -3′; MMP9, 
5′-C  C  T  G  T  G  T  G  T  T  C  C  C  G  T  T  C  A  T  C  T  -3′ and 5′-C  G  C  T  G  G  A  A  T  G  A  T  C-
T  A  A  G  C  C  C  A  -3′; TRAP, 5′-A  C  A  G  C  C  C  C  C  C  A  C  T  C  C  C  A  C  C  C  T  -3′ and 
3′-T  C  A  G  G  G  T  C  T  G  G  G  T  C  T  C  C  T  T  G  G  -5′; cathepsin K, 5′-G  G  A  A  G  A  A  G-
A  C  T  C  A  C  C  A  G  A  A  G  C  -3′ and 3′-G  T  C  A  T  A  T  A  G  C  C  G  C  C  T  C  C  A  C  A  G  -5′; 
NFATc1, 5′-T  G  C  T  C  C  T  C  C  T  C  C  T  G  C  T  G  C  T  C  -3′ and 5′-C  G  T  C  T  T  C  C-
A  C  C  T  C  C  A  C  G  T  C  G  -3′, and GAPDH, 5′-T  G  A  A  G  G  T  C  G  G  T  G  T  G  A  A  C  G-
G  A  T  T  T  G  G  C  -3′ and 3′-C  A  T  G  T  A  G  G  C  C  A  T  G  A  G  G  T  C  C  A  C  C  A  C  -5′.
Rac activation assay. Rac activation (GTP-bound Rac) was determined 
by its specifi  c binding to the p21-binding domain of PAK1 (GST-PBT) as 
described previously (61). In brief, cell lysates from pre-OCs cultured in 
VN-coated dishes and treated with M-CSF (10%) for indicated time were in-
cubated with GST-PBD fusion protein (5 μg, conjugated with glutathione-
agarose beads) for 60 min at 4°C. Bound Rac was analyzed by Western blot 
analysis using anti-Rac antibodies. Whole cell lysates were also analyzed for 
the expression of endogenous Rac for normalization.
Statistical analysis. Data were analyzed using an unpaired two-tailed Stu-
dent’s t test and are expressed as the mean plus/minus SEM. p values less than 
0.05 were considered signifi  cant.
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